AENEAS2: Aumolertinib Plus Chemotherapy Extends PFS in EGFR-Mutant Advanced NSCLC
First-line treatment for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) continues to evolve from EGFR tyrosine kinase inhibitor (TKI)…
Browsing Category